Skip to Content
Top

BY Laura Sussman

A new-generation clinical trial for glioblastoma multiforme (GBM) — the deadliest form of brain cancer – will begin enrolling patients by mid-year 2016. The trial is designed to identify effective treatments faster for this aggressive form of brain cancer which kills half of all patients diagnosed within one year. Five years after diagnosis, the survival rate is less than 2 percent.

The international trial is adaptive, meaning...

BY Ron Gilmore

A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated...

BY Ron Gilmore

An MD Anderson study may explain why chemotherapy drugs such as gemcitabine are ineffective against pancreatic cancer in some patients. The...

BY Scott Merville

A team led by researchers at MD Anderson Cancer Center reports a crucial tumor-thwarting gene protects an immune attack against lung cancer by blocking the key to an off switch on T cells, the customized warriors of the immune system. The study was published in the Journal of the National Cancer Institute.

“Identifying this role for tumor-suppressing p53 provides both a potential biomarker for response to important new cancer immunotherapy...

Study: gene protects immune attack against lung cancer

BY Jacqueline Mason

A cadre of elite surgeons is making a mark as pioneering researchers at MD Anderson. In the operating room, they’re not just excising tumors...

BY Ron Gillmore

Cetuximab, marketed as Erbitux®å, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients...

BY Clayton Boldt, Ph.D.

Diets high in meats cooked by high-temperature techniques such as barbecuing and pan-frying, which produce carcinogenic compounds, may lead...

BY Ron Gilmore

Leveraging recent advances in the biology of extracellular vesicles and their role in intercellular communication, Codiak BioSciences, Inc...

BY Ron Gilmore

MD Anderson Cancer Center was awarded more than $22 million in research grants in November from the Cancer Prevention and Research Institute...

BY Lany Kimmons

Distinguished contributions to understanding p53 tumor suppression in stem cells and breakthrough advances in treating breast cancer have...

BY Clayton Boldt, Ph.D.

National leaders and cancer center representatives recently met in Houston to review strategies for improving human papillomavirus (HPV) vaccination...

BY Jill Delsigne

People with Lynch syndrome face a high risk of colorectal cancer. But researchers think that reducing this risk may be as easy as taking a...

BY Ronda Wendler / photo by Wyatt McSpadden

Glioblastomas, or malignant gliomas, are sometimes called “grow-and-go” tumors. They make their own blood supply, which fuels the tumors’...

BY Ron Gilmore

It’s no surprise that people enjoy warm places like Hawaii, but may suffer in hostile locales such as Antarctica. A tumor suppressor gene...

BY Clayton Boldt, Ph.D.

Cancer prevention experts throughout the nation discussed new strategies for preventing skin cancer at the Texas Skin Cancer/Melanoma Screening...

BY Laura Sussman

An analysis of an international, cooperative-led trial of patients with locally advanced non-small cell lung cancer (NSCLC) has shown that...

BY Ron Gilmore

Scientists have shown why a drug widely used to treat chemotherapy-induced anemia in ovarian and breast cancer patients also may shorten survival...

BY Scott Merville

A new drug that’s based on MD Anderson research and designed to rev up an immune system assault on cancer has advanced to clinical trial both...

BY Scott Merville

MD Anderson’s Moon Shots Program has expanded its targets, adding some of the most intractable cancers to its campaign to more rapidly convert...

BY MD Anderson staff

It’s been a year since CVS Pharmacy, the nation’s second largest chain of drugstores, stopped selling tobacco, and the company claims the...

BY Bryan Tutt

A vaccine that delivers an antigen to dendritic cells, in turn activating killer T cells that can target specific cancers, is being investigated...

BY Sarah Bronson

Patients who undergo surgery are recovering faster and getting discharged sooner thanks to MD Anderson’s enhanced surgical recovery programs...

BY Clayton Boldt

For the first time, a new drug from the field of immuno-oncology has proven to extend survival for patients with advanced kidney cancer, a...

BY Laura Sussman

Rafael Pantoja had all but lost hope.

The thyroid cancer he had battled for 14 years was back and spreading.

Then, earlier this...

BY MD Anderson staff

A drug for pancreatic cancer that is also used to prevent rejection of organ transplants has been shown to delay progression of another form...

BY Scott Merville

A career-long fascination with discovering the ins and outs of T cells, our immune system’s tailor-made destroyers of infections and dysfunctional...

BY Ron Gilmore

Immatics Biotechnologies GmbH (Immatics) and MD Anderson have announced the launch of Immatics US, Inc., a new company aiming at becoming...

BY Ron Gilmore

DNA double-strand breaks (DSBs) are the worst possible form of genetic malfunction that can cause cancer and resistance to therapy. New information...

BY Ron Gilmore

An MD Anderson study has found that a protein called CSN6 is linked to poor survival among patients with colorectal cancer.

The study...

BY Ron Gilmore

Merck and MD Anderson have announced a strategic clinical research collaboration to evaluate Merck’s anti-PD-1 therapy, KEYTRUDA®å (pembrolizumab...

BY Laura Sussman

In a first-of-its-kind study, researchers at MD Anderson Cancer Center have demonstrated a benefit in overall survival among epithelial ovarian...

BY Clayton Boldt

MD Anderson has appointed former U.S. Public Health Service four-star Admiral Joxel Garcia, M.D. as the inaugural executive director of the...

BY Ron Gilmore

Scientists know that activation of growth factor receptors such as epidermal growth factor receptors (EGFR) promote tumor progression in many...

BY Scott Merville

For his groundbreaking work in immunotherapy, Jim Allison, Ph.D., chair of Immunology at MD Anderson Cancer Center, will receive the nation...

BY MD Anderson staff

Early in his career, Sam Hanash, M.D., Ph.D., faced the difficult task of telling the families and loved ones of late-stage cancer patients...

BY Ron Gilmore

MD Anderson Cancer Center has been named a site for one of two new Genome Characterization Centers (GCC) funded through the National Cancer...

BY Julie Penne

MD Anderson has been ranked the No. 1 hospital for cancer care in the nation by U.S. News & World Report’s “Best Hospitals” survey.

BY Bryan Tutt

Although the cure rate for breast cancer has risen steadily in recent decades, recurrent or metastatic disease remains difficult to control...

BY Ron Gilmore

Every parent knows the maxim “feed a cold, starve a fever.” In cancer, however, exactly how to feed or starve a tumor has not been easy to...

BY Ron Gilmore

Breast tumors may have something in common with embryos … at least in mice, say researchers at MD Anderson Cancer Center.

A study led...

BY Ronda Wendler

Women with BRCA1 mutations have a 39% risk of ovarian cancer compared to the general population’s risk of 1.3%, while women with BRCA2 mutations...

BY Clayton Boldt, Ph.D.

Hereditary colorectal cancers, caused by inherited gene mutations, are relatively rare for most patients. However, researchers at MD Anderson...

BY Clayton Boldt, Ph.D.

Mutations in the ARID1a gene, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress...

BY MD Anderson staff

It’s the Friday before Father’s Day, and V. Craig Jordan, Ph.D., who’s considered the “Father of Tamoxifen,” is sitting down to talk about...

BY Clayton Boldt, Ph.D.

The costs associated with cancer drug prices have risen dramatically over the past fifteen years, which concerns many top oncologists. In...

BY Laura Sussman

The first national review of breast-conserving therapy (BCT) shows that over the last 13 years, rates of this treatment for early-stage breast...

BY Laura Sussman

Patients with operable stage I non-small cell lung cancer (NSCLC) could achieve better overall survival rates if treated with Stereotactic...

BY MD Anderson staff

The Supreme Court’s recent ruling on same-sex marriage has cleared the way for MD Anderson Cancer Center to offer some long-awaited benefits...

BY Ron Gilmore

MD Anderson researchers believe they may have found a way to detect pancreatic cancer at an early stage, before it has spread to other organs...

BY Scott Merville

A molecule expressed by the Epstein-Barr virus is found in the B cells, bone marrow and plasma of patients with chronic lymphocytic leukemia...

BY Julie Penne

Doctors from MD Anderson and Houston Methodist Hospital have performed what is believed to be the world’s first partial skull and scalp transplant...

BY Scott Merville

MD Anderson and Madison, Wis.-based Exact Sciences Corp. have announced a partnership to co-develop and commercialize several blood-based...

BY Laura Sussman

Results of an MD Anderson clinical trial may change the perspective on a role for combination chemotherapy in advanced prostate cancer.

BY Clayton Boldt, Ph.D.

Two MD Anderson faculty members were awarded by the American Society for Clinical Oncology (ASCO) at the society’s annual meeting earlier...

BY Laura Sussman

Whole brain radiation to treat cancer that has spread to the brain is associated with significantly worse cognitive function than radiosurgery...

BY MD Anderson staff

MD Anderson Cancer Center has received more than $9 million in research grants in the latest round of funding from the Cancer Prevention and...

BY MD Anderson staff

When asked why she’s so passionate about preventing the spread of HPV, Lois Ramondetta, M.D., is quick to answer.

“Cancers are horrible...

BY Ronda Wendler

Since its introduction in the 1940s, the Pap test has been successfully detecting abnormal cells in the cervix that, if left untreated, could...

BY Ernest Hawk, M.D.

In April, new federal data was released showing e-cigarette use has tripled among students in middle and high school. We asked MD Anderson...

BY Ron Gilmore

New findings about regulation of PD-L1, a protein that allows cancer to evade the immune system, have shown therapeutic promise for several...

BY Ron Gilmore

Mutations of the KRAS gene are commonly known to lead to cancer. But deeper understanding of exactly how they do this continues to be explored...

BY Ron Gilmore

For some time, cancer scientists have considered alpha-amanitin, the toxin derived from “death cap” mushrooms, as a possible cancer treatment...

BY Ron Gilmore

Successful ovarian cancer treatment often relies on catching it early. A study at MD Anderson may help point to a new method of detecting...

BY Ron Gilmore

Cancer scientist James Allison, Ph.D., internationally known for his role in developing a new class of cancer immunotherapies, has been named...

BY Scott Merville

Approaches to cancer treatment developed by MD Anderson researchers as part of the institution’s Moon Shots Program will be, in part, the...

BY Scott Merville

Immunotherapy is complex, has curative potential for some patients when given alone or combined with other drugs, and needs further support...

BY Ron Gilmore

Think of a waterfall, and you might see why cell-signaling pathways are important to cancer research. As water cascades, it impacts everything...

BY Katrina Burton

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic...

BY Laura Sussman

The good news is death rates continue to decline for the most common types of cancer, including lung, colon, breast and prostate.

The...

BY Laura Sussman

In a study of women with high-grade uterine cancer, researchers at MD Anderson Cancer Center found sentinel lymph node (SLN) mapping accurately...

BY MD Anderson staff

A new research platform of MD Anderson’s Moon Shots Program will lead a collaboration with an international pharmaceutical company to develop...

BY Scott Merville

James Allison, Ph.D., chair of Immunology at MD Anderson Cancer Center, was awarded the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize Saturday...

BY Allison Ignacio

Christopher Logothetis, M.D., chair and professor of Genitourinary Medical Oncology, is the recipient of the inaugural Finneran Family Prize...

BY Ron Gilmore

Scientists at MD Anderson Cancer Center may have discovered why some brain cancer patients develop resistance to standard treatments including...

BY Ron Gilmore

Patrick Hwu, M.D., chair of Melanoma Medical Oncology and Sarcoma Medical Oncology at MD Anderson Cancer Center, has been named division head...

BY Ron Gilmore

It was announced last month that MD Anderson Cancer Center would be awarded more than $22 million in research grants from the Cancer Prevention...

BY Laura Sussman

In a pivotal Phase III study led by researchers at MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic...

BY Scott Merville

Triathlete and marathoner Leslie Russell teaches reading to children with dyslexia in the Spring Branch Independent School District. It’s...

BY Scott Merrville

The first experimental drug to be produced by MD Anderson’s drug discovery and development institute will kill cancer cells in a new way —...

BY Ron Gilmore

Tumors require blood to emerge and spread. That is why MD Anderson Cancer Center scientists believe targeting blood vessel cells known as...

BY Ron Gilmore

Powerful drugs known as BRAF-inhibitors have been crucial for melanoma patients, saving lives through their ability to turn off the BRAF protein...

BY MD Anderson staff

Fourteen current and former MD Anderson researchers were represented in 11 of the 50 most-cited Journal of Clinical Oncology (JCO) articles...

BY Bryan Tutt

Concurrent HIV and cancer present special challenges in the clinic, regardless of which disease is diagnosed first. The simultaneous treatment...

BY Ronda Wendler

John Mendelsohn, M.D., president of MD Anderson from 1996-2011, recently received the Texas State History Museum Foundation’s "History-Making...

BY Ron Gilmore

Ron DePinho, M.D., president of MD Anderson Cancer Center, will be inducted as a new fellow of the American Association for Cancer Research...

BY Ron Gilmore

Scottish author Robert Louis Stevenson tapped into primal fears when he penned “Dr. Jekyll and Mr. Hyde,” a 19th-century novel about a sinister...

BY Scott Merville

MD Anderson’s Moon Shots Program continues to keep the issue of indoor tanning — and its impact on teenagers — in the public eye.

The...

BY Laura Sussman

Researchers at MD Anderson have identified eight highly specific physical and cognitive signs associated with imminent death in cancer patients...

BY Ron Gilmore

When skyscrapers go up, contractors rely on an infrastructure of steel beams and braces. Some cancers grow the same way, using a biological...

BY Ron Gilmore

MD Anderson was presented the People’s Republic of China International Science and Technology Cooperation Award last month at a ceremony at...

BY Ron Gilmore

When cancer patients take part in a clinical trial to develop new therapies, they and their physicians want to know how they will feel and...

BY Laura Sussman

Thanks to the modern era of new chemotherapeutic and biologic agents available for managing their disease, patients with metastatic colorectal...

BY Ron Gilmore

MD Anderson continues to rethink how industry and academia can collaborate in deeper and broader ways to develop new drugs and bring improved...

BY Ron Gilmore

MD Anderson and AstraZeneca recently announced a multi-year strategic research collaboration to conduct multiple, parallel clinical and clinically...

BY Markeda Wade

A shorter course of radiation therapy at higher doses per fraction than the standard regimen could reduce side effects and improve quality...

BY MD Anderson staff

Feb. 4 is World Cancer Day, which was organized by the Union for International Cancer Control to raise awareness of the actions needed to...

BY Ron Gilmore

A phase two study investigating the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in...

BY MD Anderson staff

By reducing investments in medical research, any short-term savings will prove to be very costly in the long run — and not just financially...

BY Ron Gilmore

A study investigating the potential of the antifibrotic compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in...

BY Ron Gilmore

A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it’s among the most frequent chromosomal aberrations seen in many...

BY Bryan Tutt

Although primary uveal melanoma can be effectively treated with radiation or surgery, patients with metastatic disease — or those at high...

BY Scott Merville

Biotech companies Intrexon and ZIOPHARM Oncology have licensed unique MD Anderson immunotherapy technology, creating an...